Side effects and acceptability of Implanon®:: A pilot study conducted in eastern Turkey

被引:16
作者
Yildizbas, Beyhan [1 ]
Sahin, H. Guler [1 ]
Kolusari, Ali [1 ]
Zeteroglu, Salim [1 ]
Kamaci, Mansur [1 ]
机构
[1] Yuzuncu Yil Univ, Fac Med, Dept Obstet & Gynaecol, TR-65100 Van, Turkey
关键词
Implanon (R); acceptability; adverse effects; bleeding;
D O I
10.1080/13625180701442228
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective To assess side effects during the first 6 months of use of Implanon (R). Design and methods The study was conducted in eastern Turkey between June 2004 and May 2005. Forty-one healthy women, aged 18-40 years who chose to use Irriplarion (R) participated in the study. The implant was inserted between days 1 and 5 of the menstrual cycle. Findings were recorded before and during 6 months following insertion. Statistical analyses were performed using SPSS package programme including paired samples t-test. Results No pregnancy occurred during the study. Ninety days after initiation of therapy, three of the 41 patients (7.3%) had regular periods, 14 (34.1%) were amenorrhoeic and the remaining 24 (58.5%) had some type of abnormal bleeding. Dysmenorrhoea affected significantly less women (1/41, i.e. 2.4%) than before treatment (17/41, i.e. 41.5%), but mastalgia increased significantly as it was reported by five previously unaffected participants (12.2%). Mood changes appeared in seven patients (17.1%) and acne in 11 of them (26.8%). The circulating levels of protein C, total cholesterol and oestradiol dropped significantly. Endometrial thickness decreased significantly. At completion of the study period, removal of the implant was requested by eight of the 41 patients (19.5%) because of irregular bleeding (six women), depressive symptoms requiring treatment (one woman) or weight gain (one woman). Conclusions Mainly because of irregular bleeding, the discontinuation rate of Implanon(9 at 6 months among the women in this region is high (19.5%).
引用
收藏
页码:248 / 252
页数:5
相关论文
共 13 条
[1]   Menstrual bleeding patterns in untreated women [J].
Belsey, EM ;
Pinol, APY .
CONTRACEPTION, 1997, 55 (02) :57-65
[2]   Acceptability and side-effects of Implanon in switzerland: a retrospective study by the Implanon Swiss Study Group [J].
Bitzer, J ;
Tschudin, S ;
Alder, J .
EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2004, 9 (04) :278-284
[3]   Implanon use in Thai women above the age of 35 years [J].
Booranabunyat, S ;
Taneepanichskul, S .
CONTRACEPTION, 2004, 69 (06) :489-491
[4]   RETRACTED: The pharmacodynamics and efficacy of Implanon® - An overview of the data (Retracted Article) [J].
Croxatto, HB ;
Mäkäräinen, L .
CONTRACEPTION, 1998, 58 (06) :91S-97S
[5]   Metabolic effects of implantable steroid contraceptives for women [J].
Dorflinger, LJ .
CONTRACEPTION, 2002, 65 (01) :47-62
[6]   Effects on the hemostatic system and liver function in relation to Implanon® and Norplant® -: A prospective randomized clinical trial [J].
Egberg, N ;
van Beek, A ;
Gunnervik, C ;
Hulkko, S ;
Hirvonen, E ;
Larsson-Cohn, U ;
Bennink, HC .
CONTRACEPTION, 1998, 58 (02) :93-98
[7]   Clinical experience and acceptability of the etonogestrel subdermal contraceptive implant [J].
Flores, JBO ;
Balderas, ML ;
Bonilla, MC ;
Vázquez-Estrada, L .
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2005, 90 (03) :228-233
[8]   Safety and efficacy of Implanon™, a single-rod implantable contraceptive containing etonogestrel [J].
Funk, S ;
Miller, MM ;
Mishell, DR ;
Archer, DF ;
Poindexter, A ;
Schmidt, J ;
Zampaglione, E .
CONTRACEPTION, 2005, 71 (05) :319-326
[9]  
Kiriwat O, 1998, Eur J Contracept Reprod Health Care, V3, P85
[10]  
Mascarenhas L, 2000, Eur J Contracept Reprod Health Care, V5 Suppl 2, P29